Video: ESHG 2019 conference discussion panel: automated sample preparation
A result is only as good as the sample preparation that preceded it.
List view / Grid view
A result is only as good as the sample preparation that preceded it.
ESHG 2019: Automated sample preparation using magnetic bead technology and KingFisher instruments.
New opportunities for liquid biopsy: At automated workflow for isolating circulating tumor cells using KingFisher instruments.
Learn how fragment-based drug discovery improves hit rates and delivers higher-value targets using various biophysical methods.
High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes – catalytic proteins that perform chemical reactions in the cell. In this article, Matthew Lloyd discusses the opportunities and challenges associated with this approach.
Learn why researchers turned to biophysical methods to expose the molecular mechanisms of neurodegenerative diseases.
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
Learn practical tips from eight Principal Investigators about how to start your own lab.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
Tested on plaque reducing assays, researchers have identified a lead candidate multivalent carbohydrate-binding module for the treatment of COVID-19.
7 May 2020 | By PerkinElmer
High-throughput screening (HTS) cascades have evolved to ensure that high quality hits can be identified from large screening collections.
A series of three new assays to screen for drug compounds or proteins that combat the COVID-19 coronavirus has been developed.
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
Researchers investigating telomere dieases such as dyskeratosis congenita have found lead compounds that reverse cellular ageing in mouse models of the condition.
Researchers have found a lead compound which they say inhibits SARS-CoV-2 viral replication and demonstrates good pharmacokinetic activity in vivo.